Venturi G, Catucci M, Romano L, Corsi P, Leoncini F, Valensin P E, Zazzi M
Sezione di Microbiologia, Dipartimento di Biologia Molecolare, Università di Siena, Italy.
J Infect Dis. 2000 Feb;181(2):740-5. doi: 10.1086/315249.
Twenty-four adults infected with human immunodeficiency virus type 1 (HIV-1) with central nervous system symptoms were studied for antiretroviral resistance mutations in HIV-1 RNA obtained from paired cerebrospinal fluid (CSF) and plasma samples. Paired sequences were obtained from 21 and 13 patients for reverse transcriptase (RT) and for protease, respectively. Mutations conferring resistance to the RT inhibitors zidovudine, lamivudine, or nevirapine were detected in 14 patients, including 11 pretreated and 3 drug-naive subjects. The mutation patterns in the 2 compartments were different in most patients. Genotypic resistance to protease inhibitors was detected in both plasma and CSF from 1 patient treated with multiple protease inhibitors. However, accessory protease inhibitor resistance mutations at polymorphic sites were different in plasma and CSF in several patients. Partially independent evolution of viral quasispecies occurs in plasma and CSF, raising the possibility that compartmentalization of drug resistance may affect response to antiretroviral treatment.
对24名感染1型人类免疫缺陷病毒(HIV-1)且出现中枢神经系统症状的成年人进行了研究,分析从配对的脑脊液(CSF)和血浆样本中获取的HIV-1 RNA中的抗逆转录病毒耐药性突变。分别从21名和13名患者的样本中获得了用于分析逆转录酶(RT)和蛋白酶的配对序列。在14名患者中检测到了对RT抑制剂齐多夫定、拉米夫定或奈韦拉平具有耐药性的突变,其中包括11名接受过治疗的患者和3名未接受过治疗的患者。在大多数患者中,两个区室的突变模式不同。在1名接受多种蛋白酶抑制剂治疗的患者的血浆和脑脊液中均检测到对蛋白酶抑制剂的基因型耐药性。然而,在几名患者中,血浆和脑脊液中多态性位点的辅助蛋白酶抑制剂耐药性突变有所不同。病毒准种在血浆和脑脊液中部分独立进化,这增加了耐药性分区可能影响抗逆转录病毒治疗反应的可能性。